Category: Blog Post Category

Discover the impact of IDN healthcare on patient care and pharmaceutical market access strategies.

Explore strategies for leveraging healthcare IDNs to enhance market access and patient engagement.

Pharmaceutical executives are navigating through an increasingly complex regulatory landscape due to the Inflation Reduction Act (IRA).  It introduced substantial drug cost shifting and now impacts strategic and analytical planning for insurance carriers and drug manufacturers alike. This pivotal legislation brings transparency, and Medicare negotiation to drug pricing, through measures like the 2024 Catastrophic Coverage […]

ARLINGTON – CareSet released the updated DocGraph HOP Teaming Dataset during the 2022 Health Datapalooza and National Health Policy Conference. The release offers the most detailed and up-to-date picture of patient-sharing relationships between all Medicare providers in the US healthcare system. This public use file provides some of the most timely and necessary insights into […]

ARLINGTON – CareSet released the updated DocGraph HOP Teaming Dataset during the 2022 Health Datapalooza and National Health Policy Conference. The release offers the most detailed and up-to-date picture of patient-sharing relationships between all Medicare providers in the US healthcare system. This public use file provides some of the most timely and necessary insights into […]

The 40th Annual J.P. Morgan Healthcare Conference, January 10-13, brought strategic insights. This year, I spoke with Deloitte, specifically partners in the regulatory practice and leaders of the regulatory strategies group. This team seeks discussion with healthcare executives who look at the regulatory environment as input to strategy endeavors.As an industry as heavily regulated as […]

Until now, healthcare providers spent up to 40% of their time on administrative tasks, largely due to the complexity of the code system. Spending more time on paperwork meant spending less time with patients which was frustrating for everyone. Recently, the AMA revised the definitions for Evaluation and Management (E/M) codes in the Current Procedural […]

Picture the following scenario: A patient presents with symptoms including numbness, tremors, and occasional weakness, among others. Genetic testing exists to check for rare cardiovascular diseases and defects, but it is expensive and not currently listed as part of the diagnosis protocol. Because of this, his doctors didn’t order the test. He suffered from these […]

Navigating the world of Specialty Pharmacy is complex and riddled with information asymmetry.  But, it just got a lot easier. CareSet provides the experience and unblocked data to connect your new medication with the Specialty Pharmacies and prescribing physicians you need to reach your target patient populations.Characterizing the industry, the co-founder and former president of […]

In specialty pharmacies, some medications may have partially blocked data. Manufacturers, payers, and specialty pharmacies can elect to block this data. When they do, it’s no longer visible to their allied and competitive healthcare stakeholders, like yourself. CareSet’s Part D Targeting product provides brand teams clarity using Medicare’s unblocked claims data. This allows us to […]